Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 5 | 2023 | 203 | 1.970 |
Why?
|
| Kidney Failure, Chronic | 2 | 2025 | 215 | 1.270 |
Why?
|
| Peritoneal Dialysis | 1 | 2025 | 33 | 0.930 |
Why?
|
| Liver Failure | 1 | 2023 | 22 | 0.800 |
Why?
|
| Acidosis | 1 | 2023 | 41 | 0.790 |
Why?
|
| Liver Diseases | 1 | 2023 | 82 | 0.760 |
Why?
|
| Lactation | 1 | 2020 | 60 | 0.650 |
Why?
|
| Kidney Diseases | 2 | 2020 | 231 | 0.580 |
Why?
|
| Breast Feeding | 1 | 2020 | 195 | 0.570 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 35 | 0.550 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 50 | 0.530 |
Why?
|
| Renal Dialysis | 1 | 2017 | 191 | 0.490 |
Why?
|
| Thrombosis | 1 | 2018 | 260 | 0.450 |
Why?
|
| Phenazopyridine | 1 | 2014 | 3 | 0.440 |
Why?
|
| Nephritis, Interstitial | 1 | 2014 | 9 | 0.430 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 391 | 0.400 |
Why?
|
| Kidney | 4 | 2023 | 722 | 0.390 |
Why?
|
| Propylthiouracil | 1 | 2011 | 4 | 0.370 |
Why?
|
| Antithyroid Agents | 1 | 2011 | 8 | 0.370 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 5 | 0.370 |
Why?
|
| Graves Disease | 1 | 2011 | 19 | 0.370 |
Why?
|
| Veterans | 1 | 2018 | 581 | 0.360 |
Why?
|
| Nephrology | 2 | 2022 | 26 | 0.330 |
Why?
|
| Humans | 18 | 2025 | 52469 | 0.280 |
Why?
|
| TRPP Cation Channels | 1 | 2024 | 4 | 0.230 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 7 | 0.220 |
Why?
|
| Equipment Design | 1 | 2025 | 290 | 0.220 |
Why?
|
| Antirheumatic Agents | 2 | 2014 | 39 | 0.200 |
Why?
|
| Bicarbonates | 1 | 2023 | 16 | 0.200 |
Why?
|
| Sodium | 1 | 2023 | 95 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2014 | 117 | 0.190 |
Why?
|
| Antioxidants | 1 | 2023 | 257 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 599 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2023 | 588 | 0.170 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 55 | 0.160 |
Why?
|
| Uremia | 1 | 2019 | 13 | 0.150 |
Why?
|
| Urea | 1 | 2019 | 82 | 0.150 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 331 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2020 | 133 | 0.150 |
Why?
|
| Intestines | 1 | 2019 | 154 | 0.140 |
Why?
|
| Arkansas | 1 | 2023 | 2024 | 0.140 |
Why?
|
| Prevalence | 2 | 2018 | 1016 | 0.140 |
Why?
|
| Hemodialysis, Home | 1 | 2017 | 8 | 0.140 |
Why?
|
| Bacteria | 1 | 2019 | 220 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2011 | 250 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2017 | 90 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2017 | 459 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 399 | 0.110 |
Why?
|
| Publication Bias | 1 | 2014 | 14 | 0.110 |
Why?
|
| Disease Progression | 1 | 2017 | 872 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1076 | 0.110 |
Why?
|
| Publishing | 1 | 2014 | 37 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 322 | 0.110 |
Why?
|
| Azathioprine | 2 | 2011 | 13 | 0.110 |
Why?
|
| United States | 3 | 2022 | 5225 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6643 | 0.100 |
Why?
|
| Drug Industry | 1 | 2012 | 40 | 0.090 |
Why?
|
| Research Support as Topic | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 491 | 0.090 |
Why?
|
| Myeloblastin | 1 | 2011 | 4 | 0.090 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2011 | 8 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 41 | 0.090 |
Why?
|
| Heart Failure | 1 | 2017 | 579 | 0.090 |
Why?
|
| Testis | 1 | 2011 | 72 | 0.090 |
Why?
|
| Remission Induction | 1 | 2011 | 218 | 0.090 |
Why?
|
| Aged | 4 | 2023 | 10193 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 399 | 0.080 |
Why?
|
| Risk Factors | 2 | 2017 | 3945 | 0.080 |
Why?
|
| Male | 6 | 2024 | 26794 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2011 | 238 | 0.080 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 124 | 0.080 |
Why?
|
| Skin | 1 | 2011 | 420 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2017 | 5471 | 0.070 |
Why?
|
| Female | 5 | 2024 | 28192 | 0.070 |
Why?
|
| Biopsy | 2 | 2018 | 602 | 0.060 |
Why?
|
| Adult | 4 | 2017 | 14151 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 30 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 36 | 0.060 |
Why?
|
| Pedigree | 1 | 2024 | 125 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2004 | 86 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 3050 | 0.050 |
Why?
|
| Middle Aged | 4 | 2024 | 13084 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2023 | 327 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 422 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 217 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 394 | 0.040 |
Why?
|
| Permeability | 1 | 2019 | 67 | 0.040 |
Why?
|
| Mutation | 1 | 2024 | 1339 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2023 | 809 | 0.040 |
Why?
|
| Cadaver | 1 | 2018 | 95 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 222 | 0.030 |
Why?
|
| Manikins | 1 | 2018 | 35 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 144 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 55 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 139 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 135 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 129 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2017 | 81 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 671 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2017 | 363 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 464 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 282 | 0.030 |
Why?
|
| Myocardium | 1 | 2017 | 478 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 509 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1550 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2012 | 6 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 2113 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 715 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 629 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 718 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3413 | 0.020 |
Why?
|
| India | 1 | 2004 | 64 | 0.010 |
Why?
|
| Colon | 1 | 2004 | 105 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 110 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 137 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 13455 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 459 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 6708 | 0.010 |
Why?
|